Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesRadiation OncologyCommunity Health Plan Washington IMRT Coverage & P…
    Ask Trek AI about this page
    CurrentCommunity Health Plan WashingtonPolicy MC.CP.MP.69

    Intensity Modulated Radiation Therapy (IMRT)

    Customize your policy alerts

    Sign up for Community Health Plan Washington Policy MC.CP.MP.69 alerts

    Get alerted when Policy MC.CP.MP.69 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria for IMRT for Medicare health plans affiliated with Centene Corporation in MAC jurisdictions lacking CMS/MAC full coverage criteria; intended for providers and prior authorization reviewers.

    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyIntensity Modulated Radiation Therapy (IMRT)
    Policy CodePolicy MC.CP.MP.69
    Change TypeNo material change noted
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and document that the clinical indication meets one of the listed medical necessity criteria when billing IMRT delivery or planning codes.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    MultipleDistinct major criteria sections listed
    77385,77386,77301,77338,G6015,G6016

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Codes referenced
    Age <18Pediatric covered
    ASTRO/NCCNPrimary guideline sources
    ©2023Copyright year

    Coverage Criteria for IMRT

    Covered Indications

    IMRT is medically necessary when ANY one of the following indications is present:

    Top-level clinical indications: A. Age < 18 years with a solid tumor.

    Policy I.A; pediatric solid tumors

    Top-level clinical indications: B. Medically inoperable patient with diagnosis of cancer where dose escalation is required.

    Policy I.B

    Top-level clinical indications: C. Primary malignant or benign bone tumors.

    Policy I.C

    Top-level clinical indications: D. Re-irradiation where cumulative critical structure dose would exceed tolerance dose.

    Policy I.D

    Top-level clinical indications: E. Indications by cancer site (any one of the site-specific sub-indications below).

    Policy I.E

    Central Nervous System indications: Ocular tumors including intraocular melanomas; tumors that approach or are located at the base of skull; primary CNS tumors, primary spine, or metastatic tumors to the spine or spinal cord where organ-at-risk tolerance may be exceeded with 3-D conformal treatments; primary and metastatic tumors requiring craniospinal irradiation; brain metastases requiring hippocampal-sparing whole brain radiotherapy.

    Policy I.E.1

    Head and Neck indications: Definitive, adjuvant, or palliative treatment of primary/secondary head and neck cancers or draining lymphatics of the neck (including but not limited to nasopharynx, nasal cavity, paranasal sinuses, oropharynx, oral cavity, hypopharynx, larynx, thyroid, salivary glands); cutaneous tumors with cranial nerve invasion to the base of skull, cavernous sinus, and/or brainstem; mucosal melanoma; occult primary malignancies of the head and neck.

    Policy I.E.2

    Breast indications: Bilateral breast cancers requiring nodal treatment on at least one side; definitive treatment with unfavorable anatomy that would deliver unacceptably high doses to organs-at-risk; early-stage disease with unacceptably high cardiac dose using conventional techniques; accelerated partial breast irradiation (APBI) regardless of laterality; targeting internal mammary lymph nodes; limited ipsilateral arm range of motion requiring arms-down positioning; post-mastectomy radiotherapy with bilateral implant-based reconstruction; whole breast radiotherapy in patients with bilateral augmentation implants.

    Policy I.E.3

    Thoracic indications: Primary or secondary mediastinal tumors (including thymic tumors, mediastinal tumors, mediastinal lymphomas and thoracic sarcomas); early-stage lung cancer for which SBRT is not feasible due to anatomic considerations; locally advanced lung cancer where IMRT significantly reduces dose to normal tissues (e.g., bilateral mediastinal disease, paraspinal tumors, N3 disease, reducing esophageal dose); malignant pleural mesothelioma.

    Policy I.E.4

    Gastrointestinal indications: Hepatocellular cancer, bile duct, gallbladder and cholangiocarcinoma; primary cancers of the esophagus and gastroesophageal junction; abdominal malignancies including pancreatic, gastric and adrenal cancers; primary and secondary liver cancers; anal and colorectal cancers.

    Policy I.E.5

    Sarcoma indications: Retroperitoneal sarcomas; desmoid tumors; endometrial cancer; soft tissue sarcoma when organ-at-risk dose constraints cannot be met.

    Policy I.E.6

    Pelvic/Gynecological indications: Cervical cancer; vulvar and vaginal cancers; endometrial cancer.

    Policy I.E.7

    Genitourinary indications: Prostate cancer; renal cancer; bladder cancer; penile cancer; ureteral cancer.

    Policy I.E.8

    The policy includes site-specific indications drawn from guideline sources such as ASTRO and NCCN but explicitly notes that the listed anatomical sites are not intended to be an all‑inclusive enumeration of possible uses. Reviewers and treating clinicians should consider the listed sites as representative examples where IMRT is commonly considered medically necessary, and recognize that other clinically justified uses may exist that are not enumerated in this policy.

    Coverage of services described in this clinical policy is subject to the member’s specific benefit documents and the terms of the applicable contract. This policy is a guide to medical necessity and does not guarantee payment; coverage decisions and benefit administration remain subject to the member’s evidence of coverage, certificate of coverage, policy, contract of insurance, and applicable Health Plan administrative procedures.

    Within the portion of the document provided there are no discrete procedure‑level statements labeling particular uses of IMRT as ‘‘not medically necessary.’’ Implicitly, applications of IMRT that do not meet any of the medical necessity criteria listed in the policy (for example, indications not included among the site‑specific or top‑level criteria) may be considered unsupported and therefore subject to denial under the Plan’s review processes.

    Billing and Coding

    IMRT delivery CPTCPTCovered
    77385Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; simple
    IMRT delivery/planning CPTCPTCovered
    77386Intensity modulated radiation treatment delivery (IMRT), includes guidance and tracking, when performed; complex
    77301Intensity modulated radiotherapy plan, including dose-volume histograms for target and critical structure partial tolerance specifications
    77338Multi-leaf collimator (MLC) device(s) for intensity modulated radiation therapy (IMRT), design and construction per IMRT plan
    IMRT HCPCS/G-codesHCPCSCovered
    G6015Intensity modulated treatment delivery, single or multiple fields/arcs, via narrow spatially and temporally modulated beams, binary, dynamic MLC, per treatment session.
    G6016Compensator-based beam modulation treatment delivery of inverse planned treatment using three or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session

    Provider Actions, Prior Authorization & Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required when billing for IMRT delivery and IMRT planning codes. Requests for prior authorization must document that the indication meets one of the medical necessity criteria in this policy (e.g., age < 18 with a solid tumor; medically inoperable cancer where dose escalation is required; primary bone tumors; re-irradiation where cumulative critical-structure dose would exceed tolerance; or other site-specific indications listed in the policy).

    • Prior authorization required for IMRT delivery and planning codes (see coding list)
    • Requests must document how the case meets the policy medical necessity criteria
    Documentation Required

    Required Coding and Clinical Documentation

    Claims and authorization requests should reference the appropriate IMRT CPT/HCPCS codes and include supporting clinical documentation. Documentation should include diagnosis, treatment intent (curative vs palliative), prior radiation history (including cumulative doses to critical structures, if re-irradiation), treatment planning details (IMRT planning report, dose-volume histograms), and justification for IMRT vs alternative radiation techniques.

    Background and Clinical Context

    Intensity‑modulated radiation therapy (IMRT) delivers beams in which the radiation intensity is varied across each treatment field, enabling simultaneous differential dosing within a target volume. This modulation permits creation of steeper dose gradients and more conformal dose distributions than conventional techniques, improving organ‑at‑risk sparing and dose homogeneity within the planning target volume (PTV). These technical capabilities make IMRT particularly useful for tumors adjacent to critical structures, for dose escalation where higher target doses are required, and for re‑irradiation scenarios where cumulative organ tolerance is a concern. Tradeoffs include increased sensitivity to patient or target motion and potential exposure of larger low‑dose volumes compared with simpler techniques.

    Definitions

    PTV — Planning Target Volume (definition)
    DefinitionPlanning Target Volume (PTV) represents the target volume used in radiation therapy planning that accounts for tumor motion and setup variability to ensure the prescribed dose covers the clinical target.
    PurposePTV is used to encompass the Clinical Target Volume (CTV) plus margins for internal motion and setup uncertainty to achieve adequate dose delivery.
    Clinical relevancePTV margins influence dose to adjacent organs-at-risk; IMRT planning uses PTV to shape dose distributions and spare critical structures.
    IMRT — Intensity-modulated radiation therapy (definition)
    DefinitionIntensity-modulated radiation therapy (IMRT) is a technique that changes the intensity of radiation across different parts of a single beam during delivery to produce complex dose distributions.
    Capabilities
    Policy Summary
    PayerCommunity Health Plan Washington
    PolicyIntensity Modulated Radiation Therapy (IMRT)
    Policy CodePolicy MC.CP.MP.69
    Change TypeNo material change noted
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization and document that the clinical indication meets one of the listed medical necessity criteria when billing IMRT delivery or planning codes.
    SourceLink
    On This Page
    Coverage Criteria for IMRTBilling and CodingProvider Actions, Prior Authorization & DocumentationBackground and Clinical ContextDefinitions
    • Reference relevant CPT/HCPCS: e.g., 77385, 77386, 77301, 77338; G6015, G6016
    • Include IMRT plan and dose-volume histograms, QA notes, and prior radiation records when applicable
    • Document diagnosis, clinical indication, and rationale for IMRT selection
    Denial Risk

    Denial Risk for Unsupported or Undocumented Indications

    Requests that do not provide adequate clinical documentation linking the requested IMRT services to a listed medical necessity indication, or that lack required coding or treatment-planning documentation, are at risk for denial.

    • Incomplete documentation or unsupported indications may result in denial of authorization or claim payment
    Allows simultaneous treatment of multiple areas within the target to different dose levels and improves dose homogeneity compared with conventional techniques.
    BenefitsEnables organ-at-risk sparing and improved dose conformity for tumors adjacent to critical structures, as recommended by NCCN for multiple cancer types.
    ConsiderationsPotential concerns include dose inhomogeneity, increased planning and QA time, and exposure of larger volumes of normal tissue to low-dose radiation.